date:Jan 22, 2014
owth of 6-9% and an EBIT margin of 25-26%.
Today we close the books on an eventful 2013 for Novozymes, said Peder Holk Nielsen, president and CEO of Novozymes. We delivered a good finish to the year and ended at the high end of our guided ranges for sales growth and above that for earnings. We also signed a number of landmark agreements within Biomass Conversion and BioAgriculture that will enable Novozymes to change the world together with its customers. The outlook for 2014 is positive. We ex